199 related articles for article (PubMed ID: 32483732)
21. How the NOTCH pathway contributes to the ability of osteosarcoma cells to metastasize.
Hughes DP
Cancer Treat Res; 2009; 152():479-96. PubMed ID: 20213410
[TBL] [Abstract][Full Text] [Related]
22. Interleukin-12 enhances the sensitivity of human osteosarcoma cells to 4-hydroperoxycyclophosphamide by a mechanism involving the Fas/Fas-ligand pathway.
Duan X; Zhou Z; Jia SF; Colvin M; Lafleur EA; Kleinerman ES
Clin Cancer Res; 2004 Jan; 10(2):777-83. PubMed ID: 14760101
[TBL] [Abstract][Full Text] [Related]
23. Fas-negative osteosarcoma tumor cells are selected during metastasis to the lungs: the role of the Fas pathway in the metastatic process of osteosarcoma.
Koshkina NV; Khanna C; Mendoza A; Guan H; DeLauter L; Kleinerman ES
Mol Cancer Res; 2007 Oct; 5(10):991-9. PubMed ID: 17951400
[TBL] [Abstract][Full Text] [Related]
24. Class I-Histone Deacetylase (HDAC) Inhibition is Superior to pan-HDAC Inhibition in Modulating Cisplatin Potency in High Grade Serous Ovarian Cancer Cell Lines.
Bandolik JJ; Hamacher A; Schrenk C; Weishaupt R; Kassack MU
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234549
[TBL] [Abstract][Full Text] [Related]
25. Expression of c-FLIP in pulmonary metastases in osteosarcoma patients and human xenografts.
Rao-Bindal K; Rao CK; Yu L; Kleinerman ES
Pediatr Blood Cancer; 2013 Apr; 60(4):575-9. PubMed ID: 23255321
[TBL] [Abstract][Full Text] [Related]
26. Fas expression in lung metastasis from osteosarcoma patients.
Gordon N; Arndt CA; Hawkins DS; Doherty DK; Inwards CY; Munsell MF; Stewart J; Koshkina NV; Kleinerman ES
J Pediatr Hematol Oncol; 2005 Nov; 27(11):611-5. PubMed ID: 16282894
[TBL] [Abstract][Full Text] [Related]
27. Entinostat, a novel histone deacetylase inhibitor is active in B-cell lymphoma and enhances the anti-tumour activity of rituximab and chemotherapy agents.
Frys S; Simons Z; Hu Q; Barth MJ; Gu JJ; Mavis C; Skitzki J; Song L; Czuczman MS; Hernandez-Ilizaliturri FJ
Br J Haematol; 2015 May; 169(4):506-19. PubMed ID: 25712263
[TBL] [Abstract][Full Text] [Related]
28. Systemic study of selected histone deacetylase inhibitors in cardiac complications associated with cancer cachexia.
Bora V; Patel D; Johar K; Goyal RK; Patel BM
Can J Physiol Pharmacol; 2022 Mar; 100(3):240-251. PubMed ID: 34614370
[TBL] [Abstract][Full Text] [Related]
29. Histone deacetylase inhibition sensitizes osteosarcoma to heavy ion radiotherapy.
Blattmann C; Oertel S; Thiemann M; Dittmar A; Roth E; Kulozik AE; Ehemann V; Weichert W; Huber PE; Stenzinger A; Debus J
Radiat Oncol; 2015 Jul; 10():146. PubMed ID: 26178881
[TBL] [Abstract][Full Text] [Related]
30. Targeting SALL4 by entinostat in lung cancer.
Yong KJ; Li A; Ou WB; Hong CK; Zhao W; Wang F; Tatetsu H; Yan B; Qi L; Fletcher JA; Yang H; Soo R; Tenen DG; Chai L
Oncotarget; 2016 Nov; 7(46):75425-75440. PubMed ID: 27705911
[TBL] [Abstract][Full Text] [Related]
31. Entinostat for the treatment of breast cancer.
Trapani D; Esposito A; Criscitiello C; Mazzarella L; Locatelli M; Minchella I; Minucci S; Curigliano G
Expert Opin Investig Drugs; 2017 Aug; 26(8):965-971. PubMed ID: 28718331
[TBL] [Abstract][Full Text] [Related]
32. Neratinib and entinostat combine to rapidly reduce the expression of K-RAS, N-RAS, Gα
Booth L; Roberts JL; Sander C; Lalani AS; Kirkwood JM; Hancock JF; Poklepovic A; Dent P
Cancer Biol Ther; 2019; 20(5):700-710. PubMed ID: 30571927
[TBL] [Abstract][Full Text] [Related]
33. Preclinical rationale for entinostat in embryonal rhabdomyosarcoma.
Bharathy N; Berlow NE; Wang E; Abraham J; Settelmeyer TP; Hooper JE; Svalina MN; Bajwa Z; Goros MW; Hernandez BS; Wolff JE; Pal R; Davies AM; Ashok A; Bushby D; Mancini M; Noakes C; Goodwin NC; Ordentlich P; Keck J; Hawkins DS; Rudzinski ER; Mansoor A; Perkins TJ; Vakoc CR; Michalek JE; Keller C
Skelet Muscle; 2019 May; 9(1):12. PubMed ID: 31113472
[TBL] [Abstract][Full Text] [Related]
34. A systems biology approach to identify molecular pathways altered by HDAC inhibition in osteosarcoma.
Wittenburg LA; Ptitsyn AA; Thamm DH
J Cell Biochem; 2012 Mar; 113(3):773-83. PubMed ID: 21976144
[TBL] [Abstract][Full Text] [Related]
35. Combinatorial effects of histone deacetylase inhibitors (HDACi), vorinostat and entinostat, and adaphostin are characterized by distinct redox alterations.
Rivera-Del Valle N; Cheng T; Irwin ME; Donnella H; Singh MM; Chandra J
Cancer Chemother Pharmacol; 2018 Mar; 81(3):483-495. PubMed ID: 29313067
[TBL] [Abstract][Full Text] [Related]
36. The antitumor effects of entinostat in ovarian cancer require adaptive immunity.
Smith HJ; McCaw TR; Londono AI; Katre AA; Meza-Perez S; Yang ES; Forero A; Buchsbaum DJ; Randall TD; Straughn JM; Norian LA; Arend RC
Cancer; 2018 Dec; 124(24):4657-4666. PubMed ID: 30423192
[TBL] [Abstract][Full Text] [Related]
37. The HDAC3-SMARCA4-miR-27a axis promotes expression of the
Bharathy N; Berlow NE; Wang E; Abraham J; Settelmeyer TP; Hooper JE; Svalina MN; Ishikawa Y; Zientek K; Bajwa Z; Goros MW; Hernandez BS; Wolff JE; Rudek MA; Xu L; Anders NM; Pal R; Harrold AP; Davies AM; Ashok A; Bushby D; Mancini M; Noakes C; Goodwin NC; Ordentlich P; Keck J; Hawkins DS; Rudzinski ER; Chatterjee B; Bächinger HP; Barr FG; Liddle J; Garcia BA; Mansoor A; Perkins TJ; Vakoc CR; Michalek JE; Keller C
Sci Signal; 2018 Nov; 11(557):. PubMed ID: 30459282
[TBL] [Abstract][Full Text] [Related]
38. Increased Fas expression reduces the metastatic potential of human osteosarcoma cells.
Lafleur EA; Koshkina NV; Stewart J; Jia SF; Worth LL; Duan X; Kleinerman ES
Clin Cancer Res; 2004 Dec; 10(23):8114-9. PubMed ID: 15585647
[TBL] [Abstract][Full Text] [Related]
39. Class I HDAC inhibitors enhance YB-1 acetylation and oxidative stress to block sarcoma metastasis.
El-Naggar AM; Somasekharan SP; Wang Y; Cheng H; Negri GL; Pan M; Wang XQ; Delaidelli A; Rafn B; Cran J; Zhang F; Zhang H; Colborne S; Gleave M; Mandinova A; Kedersha N; Hughes CS; Surdez D; Delattre O; Wang Y; Huntsman DG; Morin GB; Sorensen PH
EMBO Rep; 2019 Dec; 20(12):e48375. PubMed ID: 31668005
[TBL] [Abstract][Full Text] [Related]
40. Inhibiting histone deacetylase 1 suppresses both inflammation and bone loss in arthritis.
Cantley MD; Fairlie DP; Bartold PM; Marino V; Gupta PK; Haynes DR
Rheumatology (Oxford); 2015 Sep; 54(9):1713-23. PubMed ID: 25832610
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
